GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

Summary

A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab-, Talquetamab-, and JNJ-79635322-based Combination Regimens in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma OBJECTIVES: To evaluate the safety and tolerability of teclistamab-, talquetamab-, and JNJ-79635322-based combination regimens over the entire treatment phase for each arm, in participants with ND-TEMM To evaluate the efficacy of teclistamab- and talquetamab-based combination regimens as induction and post-transplant maintenance treatments; JNJ-79635322-based combinations as induction and as replacement for HDT+ASCT following induction; and teclistamab in combination with talquetamab

Timeline

Start

2022-12-01

Primary completion

2028-09-15

Completion

2029-09-15

Publications

• Raab MS, Weinhold N, Kortum KM, Kronke J, Fenk R, Weisel K, Podola L, Bertsch U, Brobeil A, Mersi J, Huhn S, Arlinghaus R, Hundemer M, Bohl SR, Mai EK, Schub N, Waldschmidt J, Bassermann F, Muller-Tidow C, Heuck C, Sakabedoyan C, Khan J, Ershova E, Koster BD, Engelhardt M, Hanel M, Salwender H, Teipel R, Goldschmidt H, Einsele H, Rasche L; GMMG-HD10/DSMM-XX (MajesTEC-5) investigators. Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial. Nat Med. 2026 Jun 25. doi: 10.1038/s41591-026-04471-x. Online ahead of print.

Drugs

Indications